FDA Clearance Tracker · P180040
TRILURON
Last checked: Nov 20, 2026Latest source record: Mar 26, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Mar 26, 2019
Approved
Time to decision
180 days
Received Sep 27, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P180040
- Device name
- TRILURON
- Applicant
- Fidia Farmaceutici S.P.A.
- Applicant location
- Abano Terme
- Received
- Sep 27, 2018
- Decided
- Mar 26, 2019
- Decision
- Approved
- Supplements
- 4 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
Approval for TRILURON. The device is indicated for use in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MOZ. The earliest in FDA's data is P950027, decided May 28, 1997.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Fidia Farmaceutici S.P.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K191052 · Decided Jan 9, 2020 · 265 days after receipt
Device type: Lubricant, Personal (NUC) · Obstetrics & Gynecology
K150883 · Decided Sep 1, 2015 · 152 days after receipt
Device type: Lubricant, Personal (NUC) · Obstetrics & Gynecology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.